IL77186A0 - Pharmaceutical insulin composition - Google Patents

Pharmaceutical insulin composition

Info

Publication number
IL77186A0
IL77186A0 IL77186A IL7718685A IL77186A0 IL 77186 A0 IL77186 A0 IL 77186A0 IL 77186 A IL77186 A IL 77186A IL 7718685 A IL7718685 A IL 7718685A IL 77186 A0 IL77186 A0 IL 77186A0
Authority
IL
Israel
Prior art keywords
capsule
active ingredient
absorption
bloodstream
intestine
Prior art date
Application number
IL77186A
Other languages
English (en)
Original Assignee
Touitou Elka
Rubinstein Arnold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Touitou Elka, Rubinstein Arnold filed Critical Touitou Elka
Priority to IL77186A priority Critical patent/IL77186A0/xx
Publication of IL77186A0 publication Critical patent/IL77186A0/xx
Priority to US06/934,741 priority patent/US4910021A/en
Priority to JP61282174A priority patent/JP2633843B2/ja
Priority to EP86309305A priority patent/EP0225189B1/fr
Priority to ES198686309305T priority patent/ES2035821T3/es
Priority to AT86309305T priority patent/ATE81287T1/de
Priority to DE8686309305T priority patent/DE3686936T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
IL77186A 1985-11-29 1985-11-29 Pharmaceutical insulin composition IL77186A0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL77186A IL77186A0 (en) 1985-11-29 1985-11-29 Pharmaceutical insulin composition
US06/934,741 US4910021A (en) 1985-11-29 1986-11-25 Targeted enternal delivery system
JP61282174A JP2633843B2 (ja) 1985-11-29 1986-11-28 目標とする腸への投与システム
EP86309305A EP0225189B1 (fr) 1985-11-29 1986-11-28 Système de libération entérique actif sur l'organe cible
ES198686309305T ES2035821T3 (es) 1985-11-29 1986-11-28 Sistema de administracion enterica dirigida.
AT86309305T ATE81287T1 (de) 1985-11-29 1986-11-28 Am zielorgan wirkendes enterales abgabesystem.
DE8686309305T DE3686936T2 (de) 1985-11-29 1986-11-28 Am zielorgan wirkendes enterales abgabesystem.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL77186A IL77186A0 (en) 1985-11-29 1985-11-29 Pharmaceutical insulin composition

Publications (1)

Publication Number Publication Date
IL77186A0 true IL77186A0 (en) 1986-04-29

Family

ID=11056458

Family Applications (1)

Application Number Title Priority Date Filing Date
IL77186A IL77186A0 (en) 1985-11-29 1985-11-29 Pharmaceutical insulin composition

Country Status (7)

Country Link
US (1) US4910021A (fr)
EP (1) EP0225189B1 (fr)
JP (1) JP2633843B2 (fr)
AT (1) ATE81287T1 (fr)
DE (1) DE3686936T2 (fr)
ES (1) ES2035821T3 (fr)
IL (1) IL77186A0 (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645504B1 (en) * 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
ATE94404T1 (de) * 1988-07-21 1993-10-15 Hoffmann La Roche Insulinzubereitung.
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
DE69006662T2 (de) * 1989-08-21 1994-05-26 Hoffmann La Roche Insulinzubereitung für nicht-parenterale Verabreichung.
EP0422290A1 (fr) * 1989-10-09 1991-04-17 Eli Lilly And Company Système pour la délivrance des médicaments
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
EP0544671A4 (en) * 1990-04-18 1993-09-15 The University Of Utah Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling
EP0459516A1 (fr) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Formes d'administration orale de protéines biologiquement actifs
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FR2673376A1 (fr) * 1991-03-01 1992-09-04 Lefesvre Andre Composition pharmaceutique pour le traitement des tumeurs de kaposi.
AU1766592A (en) * 1991-06-03 1993-01-08 Merck Sharp & Dohme Limited Pharmaceutical formulations of a benzodiazepine
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
JP2650578B2 (ja) * 1992-08-27 1997-09-03 日本エランコ株式会社 硬質カプセル用ゼラチン皮膜組成物及び易溶性硬質ゼラチンカプセル
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5646184A (en) * 1993-03-25 1997-07-08 Kao Corporation Preparation for external application to the skin and novel benzoic acid derivatives
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
AU7273494A (en) * 1993-09-01 1995-03-22 Pfizer Inc. Pharmaceutical compositions containing anionic surfactants
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
AU1824195A (en) * 1994-02-24 1995-09-11 Nippon Chemiphar Co. Ltd. Oral synthetic peptide preparation
SE9400918L (sv) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
GB2303550B (en) * 1994-06-21 1998-07-08 Danbiosyst Uk Colonic drug delivery system
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
EP0806940B1 (fr) 1994-12-22 2003-04-09 AstraZeneca AB Preparations medicamenteuses aerosols
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5817624A (en) * 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
JPH10152431A (ja) * 1996-08-02 1998-06-09 Hisamitsu Pharmaceut Co Inc 経口製剤用カプセルと経口カプセル製剤
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
KR20010012402A (ko) * 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
US6030641A (en) * 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
AU3810100A (en) * 1999-03-12 2000-10-04 Basf Aktiengesellschaft Stable pharmaceutical application form for paroxetin anhydrate
EP1175390B1 (fr) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Sels disodiques, monohydrates et solvates ethanol pour liberer des agents actifs
EP1197228A4 (fr) 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co Compositions medicamenteuses destinees au traitement du cancer colorectal
EP1985701B1 (fr) 2000-01-10 2012-05-30 Novartis Vaccines and Diagnostics, Inc. Gène s'exprimant par action différentielle dans le cancer du sein
CA2359812C (fr) * 2000-11-20 2004-02-10 The Procter & Gamble Company Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
NZ527832A (en) * 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (fr) 2001-10-25 2003-04-25 Depomed, Inc. Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
WO2003048786A2 (fr) * 2001-11-30 2003-06-12 Bristol-Myers Squibb Company Configurations de pipettes et jeux de pipettes pour mesurer des proprietes electriques cellulaires
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
WO2005020879A2 (fr) * 2003-08-27 2005-03-10 Vecta Ltd. Compositions pour le traitement de pathologies qui necessitent la suppression des secretions d'acide gastrique
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20070155664A1 (en) * 2003-07-04 2007-07-05 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
EP1750755A1 (fr) * 2004-06-02 2007-02-14 Technion Research And Development Foundation, Ltd. Methodes et preparations pour augmenter la fonction intestinale
CN1296098C (zh) * 2004-09-29 2007-01-24 薛南荣 口服胰岛素保护剂
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7964215B1 (en) * 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
WO2008003769A2 (fr) * 2006-07-06 2008-01-10 Ares Trading S.A. Composition pharmaceutique orale d'anilinopyrimidine, préparation et utilisation de celle-ci
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2527360B1 (fr) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP2344593A2 (fr) * 2008-10-02 2011-07-20 Fujifilm Manufacturing Europe BV Revêtement antimicrobien
RU2537181C2 (ru) * 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
KR101716913B1 (ko) * 2009-05-18 2017-03-15 제이에스알 가부시끼가이샤 감방사선성 수지 조성물 및 화합물
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
WO2013031949A1 (fr) * 2011-09-02 2013-03-07 富士フイルム株式会社 Préparation pharmaceutique pour capsules molles, composition destinée à la préparation pharmaceutique pour capsules molles, et procédé de production de la préparation pharmaceutique pour capsules molles
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP6294457B2 (ja) 2013-03-15 2018-03-14 ワーナー チルコット カンパニー， エルエルシーＷａｒｎｅｒ Ｃｈｉｌｃｏｔｔ Ｃｏｍｐａｎｙ， Ｌｌｃ 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
CA2997915A1 (fr) 2015-09-15 2017-03-23 C.B. Fleet Company, Incorporated Compositions de bisacodyle et appareil d'administration
WO2017123634A1 (fr) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations et méthodes pour traiter la rectocolite hémorragique
CN109776764B (zh) * 2019-01-23 2020-06-02 北京化工大学 一种超交联有机聚合物材料、制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617671C3 (de) * 1967-03-07 1980-07-03 A. Nattermann & Cie Gmbh, 5000 Koeln Weichgelatine-Kapseln mit erhöhter Wärmestabilität
YU36434B (en) * 1969-05-14 1984-02-29 Sanol Arznei Schwarz Gmbh Process for obtaining gelation capsules filled with the active substance resistant to gastric juice and dissolvable in the small intestine
US4022889A (en) * 1974-05-20 1977-05-10 The Upjohn Company Therapeutic compositions of antibiotic U-44,590 and methods for using the same
US4031215A (en) * 1974-11-11 1977-06-21 Kaken Chemical Co., Ltd. Streptovaricinone C derivatives as antibiotics
US4042688A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of providing high-protein nutrition by the oral administration of a predigested protein composition
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
JPS56128714A (en) * 1980-03-07 1981-10-08 Intaretsukusu Research Corp Oral absorption-improved beta-lactam antibiotic oral dosage
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DE3046028A1 (de) * 1980-12-06 1982-07-15 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Membranpumpe
JPS57146704A (en) * 1981-03-09 1982-09-10 Hokko Chem Ind Co Ltd Improved dust preparation for agricultural purpose
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS6054313A (ja) * 1983-09-01 1985-03-28 Terumo Corp 腸管吸収性ヘパリン組成物
JPS60215633A (ja) * 1984-04-11 1985-10-29 Terumo Corp 腸管吸収性ウロキナ−ゼリポソ−ム組成物
JPS6097917A (ja) * 1983-11-01 1985-05-31 Terumo Corp 腸管吸収性ウロキナ−ゼ組成物

Also Published As

Publication number Publication date
ATE81287T1 (de) 1992-10-15
US4910021A (en) 1990-03-20
DE3686936D1 (de) 1992-11-12
DE3686936T2 (de) 1993-04-29
EP0225189A3 (en) 1987-12-16
JPS62195324A (ja) 1987-08-28
EP0225189B1 (fr) 1992-10-07
JP2633843B2 (ja) 1997-07-23
EP0225189A2 (fr) 1987-06-10
ES2035821T3 (es) 1993-05-01

Similar Documents

Publication Publication Date Title
IL77186A0 (en) Pharmaceutical insulin composition
Waziri Glycine therapy of schizophrenia.
ATE210424T1 (de) Verzoegerte freisetzung von peptiden aus pharmazeutischen zusammensetzungen
AU6770490A (en) Solid pharmaceutical compositions containing cimetidine
MY125662A (en) Pharmaceutical formulations containing darifenacin
NO883667D0 (no) Kapsel for farmasoeytisk virksomme innholdsstoffer av en droge.
CA2168732A1 (fr) Capsules de gelatine renfermant une solution d'acetaminophene fortement concentree
KR880003617A (ko) 경구용 고형제형과 그의 제조방법
IL86607A (en) Liquid medicaments for oral administration containing encapsulated drugs in non-aqueous liquid
GR3001185T3 (en) Stable solid pharmaceutical composition containing ibuprofen and codeine
CA2183862A1 (fr) Composition stabilisee pour l'administration de peptides par voie orale
GB1161439A (en) Pharmaceutical Compositions
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
EP0177342A2 (fr) Formulations orales de protéines thérapeutiques
BE1000722A4 (fr) Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale.
IE822064L (en) Composition containing human insulin and c-peptide
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
GB8611946D0 (en) Pharmaceutical preparations
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
GB1351437A (en) N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity
GB9420748D0 (en) 1,5 benzodiazepine derivatives
KR900700102A (ko) 심장질환 치료에 쓰이는 프로파페논과 퀴니딘의 지속성 조성물
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
JPS577422A (en) Crocosmia aurea "plach"
NZ219717A (en) Pharmaceutical formulations containing indomethacin, a metabolic carboxylic acid salt and a metabolisable carbohydrate